-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AZSTARYS is an innovative treatment for patients with attention deficit hyperactivity disorder (ADHD) who are six years old and older
.
It can take effect quickly and provide long-lasting symptom control.
The agreement includes a total amount of 105.
5 million U.
S.
dollars in advance and development sales milestone payments, and a commission on annual sales
.
Shanghai AGCO Biopharmaceutical Technology Co.
, Ltd.
("AGCO Biopharma"), a biomedical company focusing on the development of innovative drugs, announced on December 28, 2021 that its subsidiaries Ark Biopharmaceutical Limited and Gurnet Point Capital (GPC )'S Commave Therapeutics, SA (Commave) signed an exclusive license agreement to trade a first innovative drug AZSTARYS® for the treatment of ADHD
.
The agreement grants AGCO Baifa the exclusive right to develop, produce and commercialize AZSTARYS in Greater China
According to the terms of the agreement, AGCO Baifa paid Commave including advance payment and milestone payments for development and sales, with a total amount of US$105.
5 million
.
In addition, it also includes an annual commission based on AZSTARYS's annual sales in Greater China
"We are very pleased to announce that we are cooperating with GPC to bring this new generation of ADHD treatment to Chinese patients
.
There are more than 20 million ADHD patients in China.
"The cooperation between Corium and AGCO will greatly promote the internationalization of AZSTARYS
," said Dr.
Sophie Kornowski, senior partner of GPC.
About AZSTARYS
AZSTARYS is the first and only drug containing SDX (a prodrug of dexmethylphenidate) that can take effect within 30 minutes and control ADHD for 13 hours
.
The US FDA approved it in March 2021 for the treatment of ADHD in patients 6 years and older
About ADHD
ADHD is a common chronic neurodevelopmental disorder.
It starts in childhood and can continue to affect adulthood.
Its main characteristics are attention deficit and hyperactivity impulsive that are not commensurate with the level of development
.
ADHD involves damage to the entire life cycle, which seriously affects the patient's study, family and social life, and can easily lead to lasting behavioral and psychological problems, and there are hidden dangers of harming personal or public interests
About Gurnet Point Capital
Gurnet Point Capital is a fund focused on the healthcare field.
It was founded by Ernesto Bertarelli and Chris Viehbacher.
For decades, they have continued to carry out company management and investment work with enthusiasm and have a wealth of industry experience
.
GPC's long-term capital is deployed by an experienced team, aiming to help a new generation of companies grow and continue to explore innovative and revolutionary medical solutions
AGCO Baifa is an innovative biopharmaceutical company with a complete drug development platform.
Its rich experience in pediatric drug development and integration of a number of first or best-in-class respiratory syncytial virus (RSV) and anti-fibrosis product pipelines will Continue to help solve the vast unmet medical needs in the field of respiratory and lung diseases
.
For more information, please visit the company's official website: Investor Relations Email: IR@arkbiosciences.
com
